Ozmosi

Ozmosi — Indication-scoped drug-development intelligence built on a cross-referenced trial/drug/disease graph: more than 800,000 trials, 35,000 drugs and 4,000 diseases linked so programmes can be compared across indications. The thematic obesity cut holds 150-plus active programmes from preclinical to Phase 3, each classified by mechanism of action (incretin single/dual/tri agonists, amylin receptor agonists, INHBE and ALK7 RNAi, muscle-preservation, CB1 antagonists, rare-obesity indications), sponsor, asset name, formulation route, trial programme family (e.g. TRIUMPH, ACCOMPLISH, MARITIME)…

Ozmosi offers (Alternative, Fundamental) — Platform-wide: more than 800,000 trial records, 35,000 drug entities and 4,000 disease entities, cross-linked. Thematic obesity cut: 150-plus active programmes with mechanism, sponsor, programme-family, endpoint and efficacy-benchmark attributes. Implied density is high — three joined entity types with per-trial attributes rather than a single flat table — though per-record field counts and refresh cadence are not published.

Competitive-intelligence and portfolio-breadth benchmarking for pharma strategy and corporate development; business-development screening for licensing and acquisition targets by mechanism and phase; thematic buy-side research on the obesity/metabolic complex using mechanism-level pipeline density and efficacy-benchmark trajectories as position inputs; clinical feasibility and trial-design benchmarking against pivotal endpoints already chosen by competitors; forecasting regulatory catalyst timing from stated submission dates; and, because trials, drugs and diseases are pre-joined into a graph, a relationship-learning substrate for link-prediction models (predicting which asset-indication pairs advance) rather than a flat tabular feature set

Coverage spans US, Other, China/HK, UK; Pharmaceuticals, Health Care Technology; alternative, fundamental; equities.